Grant R. Wilkinson
#106,369
Most Influential Person Now
Grant R. Wilkinson's AcademicInfluence.com Rankings
Grant R. Wilkinsonmedical Degrees
Medical
#1340
World Rank
#1667
Historical Rank
Gastroenterology
#14
World Rank
#14
Historical Rank
Pharmacology
#102
World Rank
#131
Historical Rank

Grant R. Wilkinsonphilosophy Degrees
Philosophy
#4318
World Rank
#6792
Historical Rank
Logic
#1809
World Rank
#2652
Historical Rank

Download Badge
Medical Philosophy
Grant R. Wilkinson's Degrees
- PhD Pharmacology University of California, San Francisco
- Doctorate Medicine University of California, San Francisco
Why Is Grant R. Wilkinson Influential?
(Suggest an Edit or Addition)Grant R. Wilkinson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A physiological approach to hepatic drug clearance (1975) (1860)
- Drug metabolism and variability among patients in drug response. (2005) (1123)
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. (1998) (1106)
- Identification of functionally variant MDR1 alleles among European Americans and African Americans (2001) (1037)
- The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. (1994) (961)
- Lorazepam Is an Independent Risk Factor for Transitioning to Delirium in Intensive Care Unit Patients (2006) (875)
- In vitro and in vivo drug interactions involving human CYP3A. (1998) (834)
- Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. (1994) (795)
- Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study (2004) (676)
- The effects of age and liver disease on the disposition and elimination of diazepam in adult man. (1975) (644)
- OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. (1999) (602)
- Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism (1996) (599)
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations (1985) (490)
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein (1999) (422)
- Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. (2000) (421)
- Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. (1999) (410)
- Reduction of liver blood flow and propranolol metabolism by cimetidine. (1981) (396)
- Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans (2006) (386)
- Clearance approaches in pharmacology. (1987) (364)
- Genetic polymorphism of S-mephenytoin hydroxylation. (1989) (317)
- Genetic variability in CYP3A5 and its possible consequences. (2004) (313)
- Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. (1977) (311)
- Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. (1985) (308)
- Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism (1984) (297)
- Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. (1987) (290)
- Commentary: a physiological approach to hepatic drug clearance. (1975) (279)
- CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B 5′‐promoter region polymorphism (2000) (278)
- Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. (2003) (276)
- Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. (2005) (271)
- Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. (2001) (267)
- P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. (1999) (267)
- Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects (2003) (258)
- Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. (2006) (241)
- Effects of aging and liver disease on disposition of lorazepam (1978) (239)
- Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. (1976) (239)
- Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. (1989) (229)
- A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. (1998) (226)
- Altered Hepatic Blood Flow and Drug Disposition (1976) (206)
- Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans (1996) (202)
- Effect of fasting and obesity in humans on the 6‐hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity (1994) (201)
- Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients (2003) (201)
- Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. (1999) (191)
- Effects of age and cigarette smoking on propranolol disposition (1979) (190)
- Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities (1989) (188)
- Increased toxicity and reduced clearance of lidocaine by cimetidine. (1982) (173)
- Normal metabolism of morphine in cirrhosis. (1981) (171)
- Biological determinants of propranolol disposition in man (1978) (166)
- Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. (1987) (166)
- Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). (1978) (159)
- Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. (1980) (158)
- Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. (1984) (158)
- Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. (2006) (157)
- Interindividual variability of chlorzoxazone 6‐hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms (1995) (155)
- Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man (1978) (148)
- Direct measurement of propranolol bioavailability during accumulation to steady-state. (1978) (145)
- Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. (1984) (144)
- Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. (1974) (140)
- Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A (1999) (140)
- Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. (1987) (136)
- In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. (2001) (132)
- Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men (1993) (130)
- Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination (1979) (127)
- A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. (1999) (126)
- Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. (1999) (125)
- Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia (1978) (125)
- Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. (2009) (123)
- Pharmacokinetics of drug disposition: hemodynamic considerations. (1975) (120)
- Effects of route of administration and blood flow on hepatic drug elimination. (1975) (115)
- An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. (1998) (114)
- The reduction of lidocaine clearance by dl-propranolol: an example of hemodynamic drug interaction. (1973) (112)
- Interaction of quinidine with anticonvulsant drugs. (1976) (110)
- The effect of cirrhosis on the disposition and elimination of meperidine in man (1974) (109)
- Drug disposition and liver disease. (1975) (107)
- Influence of genetic polymorphism on the metabolism and disposition of encainide in man. (1984) (102)
- Disposition of chlordiazepoxide: Sex differences and effects of oral contraceptives (1979) (102)
- Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. (1999) (101)
- In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. (1996) (100)
- Plasma and tissue binding considerations in drug disposition. (1983) (99)
- Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. (1985) (99)
- Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6 (1998) (99)
- Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. (1990) (98)
- Effects of liver disease on drug disposition in man. (1976) (97)
- Antiarrhythmic effects of a lidocaine congener, tocainide, 2‐amino‐2',6'‐propionoxylidide, in man (1976) (96)
- Frequency distribution of dapsone N‐hydroxylase, a putative probe for P4503A4 activity, in a white population (1994) (93)
- The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration (1978) (92)
- Suppression of Ventricular Ectopic Depolarizations by Tocainide (1977) (91)
- Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding. (1988) (91)
- Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. (1977) (91)
- Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4. (1992) (90)
- Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade (1984) (86)
- The erythromycin breath test reflects P‐glycoprotein function independently of cytochrome P450 3A activity (2006) (85)
- Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier (2006) (84)
- Differences in plasma binding of drugs between Caucasians and Chinese subjects (1990) (84)
- Erythrocyte uptake and plasma binding of di phenyl hydantoin (1974) (84)
- Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output. (1968) (83)
- Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation. (1989) (82)
- Amiodarone dosing: a proposal based on its pharmacokinetics. (1983) (81)
- Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. (1988) (80)
- Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat. (1976) (76)
- Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study (2006) (75)
- CYP3A activity in European American and Japanese men using midazolam as an in vivo probe (2001) (75)
- IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP 3 A (1998) (73)
- Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. (1984) (72)
- Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. (1987) (70)
- In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam (2004) (69)
- The contribution of N‐hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects (1990) (69)
- Abnormal regulation of plasma pyridoxal 5'-phosphate in patients with liver disease. (1976) (69)
- A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 (2003) (68)
- Bupivacaine Levels in Plasma and Cerebrospinal Fluid Following Peridural Administration (1970) (67)
- The effect of cirrhosis on the disposition and elimination of meperidine in man. (1975) (67)
- MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV‐1 Infection An Adult AIDS Clinical Trials Group Study (2003) (67)
- THE EFFECTS OF AGE AND LIVER DISEASE ON THE DISPOSITION AND ELIMINATION OF DIAZEPAM IN ADULT MAN (1976) (66)
- The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog. (1978) (66)
- Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. (1999) (66)
- Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. (1999) (63)
- Perfusion-limited effects of plasma drug binding on hepatic drug extraction (1976) (62)
- Direct enantiomeric resolution of mephenytoin and its N-demethylated metabolite in plasma and blood using chiral capillary gas chromatography. (1984) (62)
- Co‐inheritance of the polymorphic metabolism of encainide and debrisoquin (1986) (61)
- Effect of acute viral hepatitis in man on the disposition and elimination of meperidine. (1975) (61)
- Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital (1986) (58)
- Induction of propranolol metabolism by rifampicin. (1983) (57)
- CYP2C9 and Oral Anticoagulation Therapy with Acenocoumarol and Warfarin: Similarities yet Differences (2004) (56)
- Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole (1996) (55)
- The disposition of propranolol. IV. A dominant role for tissue uptake in the dose-dependent extraction of propranolol by the perfused rat liver. (1973) (54)
- Propranolol disposition in renal failure. (1980) (54)
- Absorption, metabolism, and excretion of the ephedrines in man. II. Pharmacokinetics. (1968) (54)
- Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. (1996) (53)
- Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. (1986) (53)
- Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoin (1990) (51)
- Furosemide kinetics and dynamics in patients with cirrhosis (1986) (51)
- Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans (1991) (50)
- Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques (2002) (50)
- 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. (2004) (50)
- Effect of heparin administration on plasma binding of benzodiazepines. (1980) (50)
- Plasma binding of benzodiazepines in humans. (1979) (49)
- Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. (1994) (48)
- Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. (2000) (48)
- Sub-microgram estimation of morphine in biological fluids by gas-liquid chromatography. (1969) (47)
- The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man (1978) (45)
- Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. (1994) (45)
- Effect of hypotension on liver blood flow and lidocaine disposition. (1982) (44)
- Aging and benzodiazepine binding in the rat cerebral cortex. (1982) (44)
- Dietary salt increases first‐pass elimination of oral quinidine (1997) (44)
- Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans (1980) (42)
- Disposition of diazepam in young and elderly subjects after acute and chronic dosing. (1996) (42)
- S‐mephenytoin 4‐hydroxylase is inherited as an autosomal‐recessive trait in Japanese families (1987) (42)
- The disposition of dapsone in cirrhosis (1992) (41)
- Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. (1999) (40)
- Meperidine disposition in man: Influence of urinary pH and route of administration (1981) (40)
- Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions (2004) (40)
- Furosemide disposition in cirrhosis (1982) (40)
- α2HS–Glycoprotein Is Expressed at High Concentration in Human Fetal Plasma and Cerebrospinal Fluid (1993) (40)
- Reduction of liver plasma flow by caffeine and theophylline (1986) (38)
- Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine (1996) (38)
- Genetically determined drug‐metabolizing activity and desipramine‐associated cardiotoxicity: A case report (1993) (37)
- Drug Metabolites in Renal Failure (1981) (37)
- The disposition of propranolol. VII. The effects of saturable hepatic tissue uptake on drug clearance by the perfused rat liver. (1973) (37)
- Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein (2008) (36)
- Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. (1997) (34)
- Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations. (1986) (33)
- Effects of age on meperidine disposition (1985) (33)
- In vivo inhibition of human CYP1A2 activity by oltipraz (2001) (33)
- Racial Differences in Drug Response (1989) (31)
- Influence of urine pH and flow rate on the renal excretion of chlorpheniramine in man (1965) (31)
- Disposition kinetics of encainide and metabolites. (1986) (30)
- Influence of phenobarbital on factors responsible for hepatic clearance of indocyanine green in the rat: relative contributions of induction and altered liver blood flow. (1977) (29)
- Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. (1994) (27)
- Disposition of furosemide in functionally hepatectomized dogs. (1981) (27)
- Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: A cocktail study with dextromethorphan and chloroguanide alone and in combination (1999) (27)
- Drug metabolites in renal failure: pharmacokinetic and clinical implications. (1981) (26)
- The GLC Separation of Amphetamine and Ephedrines as Pentafluorobenzamide Derivatives and Their Determination by Electron Capture Detection (1970) (26)
- Clinical sedation scores as indicators of sedative and analgesic drug exposure in intensive care unit patients. (2007) (26)
- Gastric and biliary excretion of meperidine in man (1976) (26)
- High fetal blood levels of mepivacaine and fetal bradycardia. (1968) (26)
- Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. (1987) (25)
- Encainide disposition in patients with chronic cirrhosis (1986) (25)
- The effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics. (1975) (25)
- Drug metabolism and disposition : considerations in clinical pharmacology (1985) (24)
- Encainide disposition in patients with renal failure (1986) (24)
- Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine. (1989) (24)
- Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects (2002) (24)
- Urinary excretion of (—)‐methylephedrine, (—)‐ephedrine and (—)‐norephedrine in man (1965) (23)
- A new method for constant plasma drug concentrations: application to lidocaine. (1984) (23)
- Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. (1977) (22)
- Influence of debrisoquin phenotype on the inducibility of propranolol metabolism (1989) (22)
- Diazepam disposition in mature and aged rabbits and rats. (1982) (22)
- The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors. (1995) (21)
- Drug distribution and renal excretion in the elderly. (1983) (21)
- Low activity of dapsone N-hydroxylation as a susceptibility risk factor in aggressive bladder cancer. (1994) (20)
- Effect of acute alcohol ingestion on plasma pyridoxal 5'-phosphate. (1979) (19)
- Delivery of anticonvulsant drug therapy in epileptic patients assessed by plasma level analyses (1974) (18)
- The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. (1992) (18)
- Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren. (1997) (17)
- GLC determination of papaverine in biological fluids. (1974) (17)
- Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. (2003) (17)
- Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings]. (1977) (17)
- Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis (1997) (17)
- Gas chromatographic determination of mepivacaine in capillary blood. (1969) (16)
- Elevated Plasma Free Drug Concentrations of Propranolol and Diazepam During Cardiac Catheterization (1980) (16)
- Cytochrome P450 2E1 and 3A activities do not differ between Mexicans and European Americans * (2002) (16)
- Racial differences in drug response. (1989) (15)
- Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long‐term dosing (1983) (15)
- The Relationship Between Cytochrome P4502E1 Activity and Plasma Fluoride Levels After Sevoflurane Anesthesia in Humans (1997) (15)
- Identification and determination of ephedrine and its congeners in urine by gas chromatography (1965) (14)
- Frequency of impaired mephenytoin 4'-hydroxylation in an Indian population. (1990) (13)
- Geometric isomerization of doxepin during its N-demethylation in humans. (1991) (13)
- No Evidence for In Vivo Enhanced Dissociation (1989) (13)
- Chronic and severe phenobarbital intoxication in a child treated with primidone and diphenylhydantoin. (1973) (13)
- alpha 2HS-glycoprotein is expressed at high concentration in human fetal plasma and cerebrospinal fluid. (1993) (12)
- In vivo and in vitro measurement of CYP2C19 activity. (1996) (12)
- Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. (1999) (12)
- Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride–induced disease (1992) (11)
- CYP2E1 activity is not altered by influenza vaccination. (1996) (10)
- Disposition of carbamazepine and its 10,11-epoxide metabolite in the isolated perfused rat liver. (1977) (10)
- Cholestasis in transplant patients—what is the role of cyclosporin? (1992) (10)
- Watercress inhibits human CYP2E1 activity in vivo as measured by chlorzoxazone 6‐hydroxylation (1996) (10)
- The effects of ageing on the disposition of benzodiazepines in man (1979) (10)
- Sedative Plasma Concentrations and Delirium Risk in Critical Illness (2018) (9)
- Dietary Effects on Drug Metabolism (1995) (9)
- Perfusion-limited of plasma drug binding on hepatic drug extraction. (1976) (8)
- Hepatic tissue binding and the oral first-pass effect. (1984) (8)
- Impaired elimination of meperidine in patients with liver disease. (1974) (8)
- The determination of meperidine, noremeperidine and deuterated analogs in blood and plasma by gas chromatography mass spectrometry selected ion monitoring. (1980) (7)
- Reduced levels of alpha-1-antitrypsin in children exposed to high levels of air pollution. (1993) (6)
- Enantiospecific quantification of hexobarbital and its metabolites in biological fluids by gas chromatography/electron capture negative ion chemical ionization mass spectrometry. (1991) (6)
- Hepatic elimination in the rat of ditekiren (U-71038), a renin inhibitor pseudohexapeptide. (1993) (6)
- Pharmacokinetic and Pharmacological Aspects of Polymorphic Drug Oxidation in Man (1984) (5)
- The application of clearance concepts to propranolol disposition in man. (1979) (5)
- No effect of smoking on metabolism of chlordiazepoxide. (1979) (5)
- The effect of heparin on benzodiazepine binding in plasma (1979) (5)
- Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer. (1997) (5)
- Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. (1991) (5)
- In Vivo Probes for Studying Induction and Inhibition of Cytochrome P450 Enzymes in Humans (2001) (4)
- Pharmacokinetic interpretation of dicloxacillin levels in serum after extravascular administration. (1969) (4)
- Bladder cancer recurrence and its association with cytochrome P-450IID6 activity. (1992) (4)
- Erythromycin breath test (multiple letters) (2000) (4)
- The assessment of bioavailability in the presence of nonlinear elimination (1988) (4)
- Observations on the gas chromatographic behaviour of some amines used in anorectic formulations. (1967) (4)
- Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in man. (1987) (3)
- OATP and P‐glycoprotein mediate the uptake and excretion of fexofenadine (1999) (3)
- High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren. (1997) (3)
- Acute Effects of Halothane Anesthesia on Arterial and Venous Concentrations of Propranolol in the Dog (1987) (3)
- Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. (1996) (3)
- Treatment of drug intoxication: a review of some scientific principles. (1970) (3)
- Physiological factors affecting hepatic first-pass metabolism (1982) (3)
- Identification and Functional Characterization of a New CYP 2 C 9 Variant ( CYP 2 C 9 * 51 ) Expressed among African Americans (2001) (2)
- Proceedings: High-affinity hepatic microsomal binding of propranolol: its relationship to metabolism and to the first-pass effect. (1974) (2)
- Proceedings: Presystemic hepatic elimination. (1974) (2)
- New up-conversion luminescence in molecular cyano-substituted naphthylsalophen lanthanide(III) complexes. (2021) (2)
- 918 – EFFECT OF DRUG CONCENTRATION AND ENZYME INDUCERS ON INDOCYANINE GREEN CLEARANCE IN THE RAT (1977) (2)
- 2301 – AGE RELATED EFFECTS OF SMOKING ON ELIMINATION OF PROPRANOLOL (P) ANTIPYRINE (Ap) AND INDOCYANINE GREEN (ICG) (1978) (2)
- Suppression ofVentricular Ectopic Depolarizations byTocainide (1977) (1)
- Tariquidar (TAR, XR‐9576) selectively inhibits P‐glycoprotein (P‐gp) in t‐lymphocytes compared to that in the blood‐brain barrier (BBB) (2005) (1)
- pharmacokinetic consequences Polymorphism of propafenone metabolism and disposition in man: clinical and (2011) (1)
- Prediction of midazolam (MDZ) clearance (CL) using minimized sampling (MS) of 1-OHM and 1-OHM/MDZ in healthy subjects (HS) (2001) (1)
- Tacial differences of Midazolam clearance. Comparison of Japanese and white races. (1998) (0)
- Reduction of Liver Blood Flow and Propranolol Metabolism by Cimetidine (1981) (0)
- Plasma Binding, Distribution, and Elimination (2020) (0)
- Lack of genotype: phenotype associations between CYP3A4*1B, CYP3A5*3C, CYP3A5*6 and midazolam metabolism in european‐ and african‐americans (2003) (0)
- Recurrence of bladder cancer is associated with cytocjrome P450llD6 debrisoquine 4-hydroxylase activity (1991) (0)
- DRUG DISPOSITION: HEMODYNAMIC CONSIDERATIONS (1975) (0)
- Cytochrome P450IIIA-mediated hydroxylation of dapsone in normal subjects and cirrhotics (1990) (0)
- Lack of genotype: phenotype associations between CYP3A4*1B, CYP3A5*3C, CYP3A5*6 and midazolam metabolism in european‐ and african‐americans (2003) (0)
- Suppression of Ventricular Ectopic Depolarizations (2005) (0)
- 2897 – THE INFLUENCE OF CIRRHOSIS ON FREE PROPRANOLOL CONCENTRATION DURING CHRONIC ORAL ADMINISTRATION (1978) (0)
- Usefulness of Dextromethorphan as in vivo CYP3A active index drugs. (1997) (0)
- The pharmacogenetics of bladder cancer Hydroxylation pathways and cytochrome P450 activity (1993) (0)
- DIRECTMEASUREMENTOF PROPRANOLOLBIOAVAILABILITY DURINGACCUMULATIONTO STEADY-STATE (1978) (0)
- Pyridoxal 5′-Phosphate (Plp) (2009) (0)
- LIVER PHYSIOLOGY AND DISEASE ABNORMAL REGULATION OF PLASMA PYRIDOXAL 5'·PHOSPHATE IN PATIENTS WITH LIVER DISEASE (1976) (0)
- Proceedings: Pharmacokinetics of diazepam in man. (1974) (0)
- Correlation between the CYP3A‐mediated oral clearances of alprazolam, midazolam and triazolam (2004) (0)
- The pharmacokinetics and clinical importance of polymorphic drug oxidation (1990) (0)
- OIV‐B‐1 (2006) (0)
- DRUG METABOLISM AND INTERINDIVIDUAL DIFFERENCES IN DRUG RESPONSIVENESS (1992) (0)
- Molecular cloning, genomic organization, and tissue distribution of the human MRP3 transporter and its splice variants (1999) (0)
- Deuterium labelling of the antidepressant drug doxepin for disposition studies in human subjects (1990) (0)
- PHARMACOKINETICS OF THE FIRST PASS EFFECT (1976) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Grant R. Wilkinson?
Grant R. Wilkinson is affiliated with the following schools: